title: Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers.
abstract: Multidrug resistance is probably the single greatest obstacle to successful systemic therapy of human cancer. We have reported that cyclosporin A (CsA) can overcome multidrug resistance and improve the efficacy of etoposide in a murine model of drug-sensitive leukemia. The combination of CsA and paclitaxel (PCL) was also significantly superior to either drug alone against murine P388 (sensitive) and L1210 (resistant) leukemia. Lung cancer cells provide an ideal model system to study this phenomenon because both de novo and acquired drug resistance occur. Standard chemotherapy for advanced lung cancer is poorly effective, and although PCL is one of the most active new agents for this disease, responses occur in only 20% of patients. In vitro, CsA significantly enhanced the efficacy of PCL against lung (Lu-CSF-1 and 3LL) and oropharyngeal (CSCC-20) cancer cell lines. The combination also produced an increase in expression of interleukin 1beta, a cytokine known to inhibit the growth of Lu-CSF-1 cells. CsA alone had little or no antiproliferative activity in vitro and did not alter PCL transport. These results indicate that the activity of chemotherapy modulators may extend beyond mitigation of drug resistance to enhancement of therapeutic efficacy against drug-sensitive tumor cells in vitro and in vivo.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of California, Irvine, California 92717, USA.
authors.forename: H J
authors.initials: HJ
authors.lastname: Ross
authors.forename: A L
authors.initials: AL
authors.lastname: Canada
authors.forename: L M
authors.initials: LM
authors.lastname: Slater
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D005990:Glycerol / Q000031:analogs & derivatives / Q000494:pharmacology; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007938:Leukemia / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D051379:Mice; D017239:Paclitaxel / Q000627:therapeutic use*; D012142:Respiratory Tract Neoplasms / Q000188:drug therapy* / Q000276:immunology; D015996:Survival Rate; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016207:Cytokines; D006133:Growth Substances; D007166:Immunosuppressive Agents; C000515:cremophor EL; D016572:Cyclosporine; D017239:Paclitaxel; D005990:Glycerol